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Available online 16 October 2017Background:Alisertib (MLN8237) is an investigational, oral, selective Aurora A kinase inhibitor. Aurora A contains
two functional single nucleotide polymorphisms (SNPs; codon 31 [F/I] and codon 57 [V/I]) that lead to functional
changes. This study investigated the prognostic and predictive significance of these SNPs.
Methods: This study evaluated associations between Aurora A SNPs and overall survival (OS) in The Cancer Ge-
nome Atlas (TCGA) database. The Aurora A SNPs were also evaluated as predictive biomarkers for clinical out-
comes to alisertib in two phase 2 studies (NCT01045421 and NCT01091428). Aurora A SNP genotyping was
obtained from 85 patients with advanced solid tumors receiving single-agent alisertib and 122 patients with ad-
vanced recurrent ovarian cancer treated with alisertib plus weekly paclitaxel (n = 62) or paclitaxel alone (n =
60). Whole blood was collected prior to treatment and genotypes were analyzed by PCR.
Findings: TCGA data suggested prognostic significance for codon 57 SNP; solid tumor patients with VV and VI al-
leles had significantly reduced OS versus those with II alleles (HR 1.9 [VI] and 1.8 [VV]; p b 0.0001). In
NCT01045421, patients carrying the VV alleles at codon 57 (n = 53, 62%) had significantly longer progression-
free survival (PFS) than patients carrying IV or II alleles (n= 32, 38%; HR 0.5; p= 0.0195). In NCT01091428, pa-
tients with the VV alleles at codon 57 who received alisertib plus paclitaxel (n = 47, 39%) had a trend towards
improved PFS (7.5months) vs paclitaxel alone (n=32, 26%; 3.8months; HR0.618; p=0.0593). In the paclitaxel
alone arm, patients with the VV alleles had reduced PFS vs modified intent-to-treat (mITT) patients (3.8 vs
5.1months), consistentwith the TCGA study identifying the VV alleles as a poor prognostic biomarker. No signif-
icant associations were identified for codon 31 SNP from the same data set.
Interpretation: These findings suggest that Aurora A SNP at codon 57 may predict disease outcome and response
to alisertib in patients with solid tumors. Further investigation is warranted.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Correlative analysisllennium Pharmaceuticals, Inc.,
. This is an open access article under1. Introduction
Aurora A kinase (AAK), a member of the conserved serine/threonine
protein kinase family, is a key mitotic regulator with a critical role inthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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alignment, and cytokinesis (Barr and Gergely, 2007; Marumoto et al.,
2003). Overexpression and/or amplification of AAK has been observed
in a variety of cancers (Dar et al., 2008; Hoque et al., 2003; Mazumdar
et al., 2009) and tends to be associated with a poor patient outcome
(Nikonova et al., 2013). Furthermore, AAK inhibition results in mitotic
progression abnormalities leading to cell death (Marumoto et al., 2003;
Gorgun et al., 2010; Zhou et al., 2013). As such, AAK represents an attrac-
tive target for anti-cancer therapy.
Aurora A is an oncogene located on chromosome 20q13.2, a locus fre-
quently amplified in solid tumors (Bischoff et al., 1998). Two functional
single nucleotide polymorphisms (SNPs) (rs2273535 and rs1047972)
in Aurora A gene, located at codon 31 and codon 57 in the NH2-terminal
region of the Aurora A protein, have been reported to be associated with
functional consequences and increased cancer risk (Chen et al., 2007,
2015; Ewart-Toland et al., 2005; Kimura et al., 2005; Miao et al., 2004).
The T91A SNP at codon 31 results in a phenylalanine to isoleucine
(F31I) change; homozygous T/T at this locus codes for FF, T/A leads to
FI, and A/A codes for II. This SNP is associated with increased frequency
of aneuploidy in human colon tumors (Ewart-Toland et al., 2005), in-
creased breast cancer risk, especially in Asian patients (Dai et al., 2004),
and lowpenetrance cancer susceptibility for other cancer types including
lung and oesophageal cancer (Ewart-Toland et al., 2005). TheG169A SNP
at codon 57 results in a valine to isoleucine amino acid substitution
(V57I); homozygous A/A genotype at this locus codes for II, A/G leads
to IV, and G/G codes for VV. Studies indicate the II variant reduces AAK
activity (Kimura et al., 2005), and may be a protective factor for risk of
developing cancer, especially in Caucasian patients and thosewith breast
cancer (Dai et al., 2004). Studies investigating the association between
Aurora A SNPs and clinical outcomes are limited. The heterozygous A/T
at codon 31 (FI) has been shown to be associated with a significantly
higher risk of tumor relapse, shorter disease-free survival, and shorter
median survival time in oesophageal cancer patients treatedwith preop-
erative chemoradiation (Pan et al., 2012). In particular, in patients treat-
ed with cisplatin-based chemoradiation, this genotype at codon 31 was
associated with poor response and shorter survival (Pan et al., 2012).
The variant I31/V57 haplotype also carried a significant risk for a low
rate of complete response and higher recurrence rate (Pan et al., 2012).
The investigational oral agent alisertib (MLN8237) is a selective,
small-molecule AAK inhibitor that has demonstrated preclinical activity
against a broad range of tumor types (Manfredi et al., 2011; Sehdev et
al., 2013). In pilot studies, alisertib demonstrated antitumor activity
with manageable toxicity in patients with solid tumors (Cervantes et
al., 2012; Melichar et al., 2015) and haematological malignancies
(Goldberg et al., 2014; Kelly et al., 2014). Twophase 2 clinical trials inves-
tigating single-agent alisertib (NCT01045421) in patients with advanced
solid tumors, or alisertib in combination with weekly paclitaxel
(NCT01091428) in patients with recurrent ovarian cancer, have recently
been completed (Coleman et al. 2014 ESMO Congress) (Melichar et al.,
2015). In NCT01045421, an overall response rate (ORR) of 13% was re-
ported in the response-evaluable population, with patients in the breast
cancer and small-cell lung cancer (SCLC) cohorts showing response rates
of 18% and 21%, respectively (Melichar et al., 2015). In NCT01091428,
alisertib plus weekly paclitaxel significantly increased median progres-
sion free survival (PFS) compared with paclitaxel alone (hazard ratio
[HR] 0.740 [80% CI 0.563, 0.971]) (Falchook et al. manuscript submitted
in parallel).
Although alisertib has demonstrated promising clinical activity, its ef-
ficacy has been variable (Friedberg et al., 2014; Goldberg et al., 2014;
Matulonis et al., 2012; Melichar et al., 2015). Therefore, it is important
to identify potential predictivemarker(s) that could be used to select pa-
tients likely to benefit from alisertib treatment (Hadley and Hendricks,
2014; Kap et al., 2016). This study aimed to assess the potential associa-
tion between two Aurora A SNP genotypes (rs2273535 and rs1047972)
at codons 31 and 57, and clinical endpoints in patients from the
NCT01045421 and NCT01091428 trials.2. Methods
2.1. Study Design and Participants
The Cancer Genome Atlas (TCGA) database was searched for 10,403
patients with solid tumors who had recorded information on the SNPs
of interest. RNA sequencing (RNA-seq) and overall survival (OS) data
from10,034 patient sampleswere available to assess the association be-
tween Aurora A SNP genotypes and OS. Since the SNPs are not somatic
mutations and there are no reported cases with somatic mutations at
those sites, variants found from RNA-Seq can be thought of as germline
SNPs. The genotypes of a particular SNP were called based on the allele
fraction of its SNP allele.
Details of bothphase 2 alisertib studies have beenpublishedprevious-
ly (Melichar et al., 2015); additional study information (patient consent,
treatment regimen, and study endpoints) can be found in the appendix.
In brief, NCT01045421 was an open-label, multicentre study of single-
agent alisertib in 249 adult patientswith advanced, relapsed solid tumors
including breast cancer, small cell lung cancer (SCLC), non-SCLC (NSCLC),
head and neck squamous-cell carcinoma (HNSCC), and gastro-oesopha-
geal adenocarcinoma (GE). NCT01091428 was a randomised, open-
label study of alisertib plus weekly paclitaxel compared with paclitaxel
alone in 142 adult patients with previously treated recurrent epithelial
ovarian, fallopian tube, or primary peritoneal cancer. Correlative analyses
of Aurora A SNPs and clinical efficacy outcomes were conducted in the
subgroup of patients (85 of 249) from the study NCT01045421 and the
subgroup of patients (122 of 142) from the study NCT01091428.
2.2. Procedures
To analyze Aurora A SNP data in TCGA, SNPs were genotyped based
on RNA-seq results from patients (see appendix for details). Once geno-
types at the SNP sites were assigned to each sample, the potential asso-
ciation between genotype andOSwas investigated. At each SNP site (i.e.
codon 31 and codon 57), survival curves for the three strata (homozy-
gous reference, heterozygous, and homozygous SNP) were plotted and
HR were calculated using the Cox proportional hazard model with re-
spect to homozygous reference (FF at codon 31 and II at codon 57),
with no clinical covariates considered; the p-value was computed
using χ2 (Marumoto et al., 2003) test.
Whole blood samples were collected prior to administration of
alisertib or paclitaxel, and genomic DNA was isolated from peripheral
blood mononuclear cells. Aurora A SNP genotypes were analyzed by
real-time polymerase chain reaction (PCR; see appendix for details).
Whole exome next-generation sequencing (NGS) was also carried out
on a subset of tumor samples (from 47 patients) from NCT01045421.
Details of the statisticalmethodology utilized in both phase 2 studies
have been previously described (Melichar et al., 2015). In this analysis, a
correlative study was performed to assess the relationship of Aurora A
SNP genotypes with alisertib treatment outcomes (PFS, best tumor
size change, and best response). For NCT01045421, a Cox regression
model was used to analyze possible associations between Aurora A
SNPs and PFS, stratified by tumor indication. The p-value was adjusted
for tumor indication. Analysis of variance (ANOVA)was used to analyze
best tumor size change, adjusting for tumor indication and baseline
tumor size. A simpleΧ2 (Marumoto et al., 2003) test on the contingency
table was used to test the independence between genotype and patient
response status. For NCT01091428, PFS was analyzed using log-rank
test to compare treatment arms in different populations.
3. Results
3.1. Prognostic Implication of Aurora A SNP at Codon 57
We analyzed Aurora A SNP data derived from 10,403 cancer pa-
tients with 33 different cancer types in the TCGA database; VV
52 H. Niu et al. / EBioMedicine 25 (2017) 50–57were the most frequent alleles at codon 57 (5649). The distribution
of Aurora A SNPs in patients with different tumor types was similar
to population data in the dbSNP database (data not shown). A similarFig. 1.OS in TCGA patients with solid tumors according to Aurora A SNPs at A) codon 57 (all sol
(all solid tumors). CI, confidence interval; GE, gastro-oesophageal adenocarcinoma; HNSCC, hea
OS, overall survival; SNP, single nucleotide polymorphism; TCGA, The Cancer Genome Atlas.pattern of Aurora A SNP distribution at codons 57 and 31 was seen in
the NCT01045421 and NCT01091428 populations (Supplementary
Fig. 1).id tumors), B) codon 57 (breast, HNSCC, NSCLC, GE, and ovarian cancers), and C) codon 31
d and neck squamous-cell carcinoma; HR, hazard ratio; NSCLC, non-small cell lung cancer;
53H. Niu et al. / EBioMedicine 25 (2017) 50–57Using the data in the TCGA database, we carried out a correlative
study to assess the potential association between Aurora A SNP geno-
types and OS from 10,034 patients whose survival data were available
for the analysis. The prognostic significance of codon 57 SNPwas evident
across tumor types and stages. In patients with solid tumors, II alleles at
codon 57 (2548) were associated with improved OS compared with IV
(1837) or VV (5649) alleles (IV: HR 1.9 [95% CI 1.6, 2.1]; VV: HR 1.8
[95% CI 1.6, 2.1]; p b 0.0001); OS was similar in patients with IV or VV al-
leles (Fig. 1A). In patients with tumors relevant to the phase 2 studies
(breast, HNSCC, NSCLC, GE, and ovarian), II at codon 57 (308) was
again associated with improved OS compared with IV (749) or VV
(2325) (IV: HR 1.5 [95% CI 1.1, 2.0]; VV: HR 1.4 [95% CI 1.1, 1.9]; p =
0.0184; Fig. 1B). Patients with solid tumors carrying II at codon 31
(604) demonstrated a decrease in OS comparedwith patients with FF al-
leles (7197) (HR 1.4 [95% CI 1.2, 1.6]; p b 0.0001; Fig. 1C), although the
number of patients with II alleles was limited (604).
3.2. Predictive Potential of Aurora A SNPs for Alisertib Treatment Outcomes
We assessed potential associations between Aurora A SNPs and
alisertib clinical efficacy (PFS, best tumor size change, and best re-
sponse). In total, 85 patients from the NCT01045421 study and 122 pa-
tients from the NCT01091428 study (62 in the alisertib plus paclitaxel
arm and 60 in the paclitaxel alone arm) with evaluable clinical data
were genotyped forAurora A SNPs. No significant associationswere iden-
tified for codon 31 SNP (Supplementary Fig. 2); therefore, this SNP was
not described further in this study.
Demographics and baseline characteristics for response-evaluable
patients with genotyping data available for codon 57 are shown in
Table 1. Overall, characteristics were comparable with the overall popu-
lations for each study. Although numbers were small, a greater propor-
tion of patients in NCT01091428 with II alleles (n = 4) rather than VV
or IV at codon 57 (n= 118) had a long period to relapse since receiving
prior platinum therapy, consistent with the TCGA data indicating that II
alleles at codon 57 are a positive prognostic marker.
As no somatic mutations have been found in the Aurora A gene thus
far, in TCGA or the phase 2 clinical trials, germline SNPs are identical to
tumor DNA. In this analysis, it was assumed that SNPs detected in
blood samples will be the same as those in the patients' tumors, and
may lead to differential Aurora A kinase activity. Correlative analysis
showed that patients treated with alisertib in the NCT01045421 studyTable 1
Demographics and baseline characteristics for response-evaluable patients with genotyping da
NCT01045421 Overall mITT population
(N= 249)
Median age, years (range) 61 (30–88)
Male/female, n (%) 141 (57)/108 (43)
Race, n (%)
White 231 (93)
Black/African American 12 (5)
Other/not reported 6 (2)
NCT01091428 Overall mITT population
(N= 142)
Median age, years(range) 62 (30–81)
Male/female, n (%) 0/142 (100)
Race, n (%)
White 121 (85)
Black/African American 8 (6)
Other/not reported 13 (9)
Months of relapse since prior platinum therapy, IVR n (%)
Refractory 18 (13)
0–≤6 months 71 (50)
N6–12 months 53 (37)
IVR, interactive voice response; mITT, modified intent-to-treat; SNP, single nucleotide polymorwho carried VV alleles at codon 57 had significantly increased PFS com-
pared with patients with the IV or II alleles (HR 0.5 [95% CI 0.28, 0.89]; p
= 0.0195; Fig. 2). Similar PFS improvements were seen among different
tumor types in a subgroup analysis; GE patientswhohadVV alleles had a
significant improvement in PFS compared with patients with the II or IV
alleles (HR 0.16 [95% CI 0.04, 0.65]; p = 0.0103; Fig. 3A), although total
patient numbers were small. Similarly, patients with SCLC, HNSCC, or
NSCLC who had VV alleles also had improved PFS compared with pa-
tients with the II or IV alleles (Figs. 3B–D). In contrast, patients treated
with alisertib who had breast cancer and were carrying VV alleles were
associated with a trend towards reduced PFS compared with patients
with II or IV alleles (HR 3.8 [95% CI 0.94, 15]; p = 0.0608; Fig. 3E). It is
worth noting that among 11 VV breast cancer patients analyzeanalyzed,
five had triple-negative breast cancers, a subtype previously associated
with a minimal response to alisertib (Melichar et al., 2015). Overall,
there was a trend towards improved tumor size reduction from baseline
in patients with VV vs IV vs II alleles at codon 57 (p = 0.0776; p-value
adjusted by tumor type; Fig. 4A); also when VV was compared with IV
or II alleles (p = 0.074; p-value adjusted by tumor type; Fig. 4B). The
same was true when IV was grouped with VV and compared with II (p
= 0.0545; p-value adjusted by tumor type; Fig. 4C). Best response (CR
+PR) assessed by Response Evaluation Criteria In Solid Tumors (RECIST)
was comparable between groups (5 [16%] vs 6 [11%] patients; p=0.811;
Fig. 5).
In NCT01091428, the 47 patientswith the VV alleles at codon 57who
received alisertib plus paclitaxel demonstrated an improved PFS com-
pared with the 32 patients who received paclitaxel alone (7.5 vs
3.8 months; HR 0.618 [95% CI 0.37, 1.03]; p = 0.0593; Fig. 6A). This
PFS benefit was greater than in the overall modified intent-to-treat
(mITT) population (7.6 vs 5.1 months; HR 0.74 [95% CI 0.49, 1.12]; p =
0.1534; Fig. 6B). Paclitaxel-treated VV patients had reduced PFS com-
pared with the overall mITT population (3.8 vs 5.1 months), which fur-
ther implicates VV as a poor prognostic biomarker. Similarly, although
the number of patients was small (n = 3; n = 1), those with II alleles
showed improved PFS in both arms (alisertib plus paclitaxel 9.2months;
paclitaxel alone 13.3 months).
Intra-arm comparisons showed that patients treated with alisertib
plus paclitaxel who had VV alleles had a similar outcome to patients
with IV and II alleles (median PFS 7.5 vs 7.6 months; p= 0.651; Supple-
mentary Fig. 3A). Patients treated with paclitaxel alone who had VV al-
leles had 3.8 months median PFS compared with 5.1 months inta in phase 2 alisertib studies.
Codon 57 SNP genotype
VV
(n = 53)
IV
(n= 27)
II
(n = 5)
Total
(N= 85)
57 (30–88) 62 (33–76) 63 (36–68) 57 (30–88)
33 (62)/20 (38) 18 (67)/9 (33) 1 (20)/4 (80) 52 (61)/33 (39)
45 (85) 25 (93) 5 (100) 75 (88)
5 (9) 1 (4) 0 6 (7)
3 (6) 1 (4) 0 4 (5)
Codon 57 SNP genotype
VV
(n= 94)
IV
(n = 24)
II
(n = 4)
Total
(N= 122)
62 (30–81) 65 (48–81) 62 (52–74) 62 (30–81)
0/94 (100) 0/24 (100) 0/4 (100) 0/122 (100)
77 (82) 22 (92) 4 (100) 103 (84)
7 (7) 1 (4) 0 8 (7)
10 (11) 1 (4) 0 11 (9)
9 (10) 5 (21) 0 14 (11)
54 (57) 11 (46) 1 (25) 66 (54)
31 (33) 8 (33) 3 (75) 42 (34)
phism.
Fig. 2. PFS according to Aurora A SNP at codon 57 in patients treatedwith alisertib in the NCT01045421 study. p-Value calculated using proportional hazardmodel and stratified by tumor
indication. CI, confidence interval; HR, hazard ratio; PFS, progression-free survival; SNP, single nucleotide polymorphism.
54 H. Niu et al. / EBioMedicine 25 (2017) 50–57patients with IV and II genotypes (p = 0.400; Supplementary Fig. 3B).
There was no significant association between codon 57 Aurora A SNP
and objective response to alisertib (data not shown).
4. Discussion
The results from this retrospective correlative study suggest that the
Aurora A SNP at codon 57may have prognostic and predictive value forFig. 3. PFS according to Aurora A SNP at codon 57 in patients treated with alisertib in the NCT01
interval; GE, gastro-oesophageal adenocarcinoma;HNSCC, head and neck squamous-cell carcin
single nucleotide polymorphism.cancer patients, and may provide a possible patient selection strategy
for treatment with alisertib in some cancers.
In all tumor types analyzed in the TCGA database, regardless of
stage and treatment history, patients carrying the II alleles at codon
57 had a significantly improved OS compared with patients with
the VV and VI alleles (p b 0.0001). Therefore, the II alleles at codon
57 could be considered a favorable prognostic biomarker in cancer
patients.045421 studywith A) GE, B) SCLC, C) HNSCC, D) NSCLC, or E) breast cancer. CI, confidence
oma; HR, hazard ratio; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; SNP,
Fig. 4. Percentage tumor size change from baseline in patients treatedwith alisertib in the
NCT01045421 study according to Aurora A SNP at codon 57: A) II vs IV vs VV, B) II or IV vs
VV, and C) II vs IV or VV. p-Value calculated by ANOVA, adjusted for tumor indication, SNP,
single nucleotide polymorphism.
55H. Niu et al. / EBioMedicine 25 (2017) 50–57The predictive potential of this Aurora A SNP for alisertib response
was supported by correlatives studies in two independent trials investi-
gating alisertib as a single agent or in combination with paclitaxel in
solid tumors. In the NCT01045421 study, which enrolled patients with
breast cancer, SCLC, NSCLC, HNSCC, and GE, patients with VV alleles at
codon 57 had significantly improved PFS compared with patients with
the IV or II alleles. Although patient numbers were small, PFS improve-
ments were demonstrated across different tumor types, with theFig. 5. Best response (CR + PR; RECIST v1.1) in patients treated with alisertib in the
NCT01045421 study according to Aurora A SNP at codon 57. CR, complete response; PD,
progressive disease; PR, partial response; RECIST, Response Evaluation Criteria In Solid
Tumors; SD, stable disease; SNP, single nucleotide polymorphism.exception of breast tumors. This could be due to the fact that among
the 11 VV breast cancer patients analyzed, five had triple-negative
breast cancers, while only two out of eight II/IV patients had triple neg-
ative breast cancers. As previously reported in heavily-pretreated breast
cancer patients, hormone receptor-positive and human epidermal
growth factor receptor 2 (HER2)-positive subgroups responded to
alisertib treatment, but minimal activity was seen in the triple-negative
subtype (Melichar et al., 2015). Patient subgrouping based on HER2 and
estrogen receptor (ER) status may override the ability of the Aurora A
SNP to predict sensitivity to alisertib.
In the NCT01091428 study, ovarian cancer patients treated with
alisertib plus paclitaxel did not demonstrate a difference in PFS within
the arm of patients with VV versus IV or II, which is likely due to the
fact that IV and II patients have a better prognosis in responding to pac-
litaxel. However, patients with VV demonstrated a trend towards im-
proved PFS with alisertib plus paclitaxel versus paclitaxel alone, with a
slightly greater apparent treatment effect than in the mITT population.
The apparent greater PFS benefitwith alisertib plus paclitaxel versus pac-
litaxel alone inVV comparedwith IV or II patients ismainly due to poorer
outcomeswith paclitaxel in VV-carrying patients, although thismay be a
multifactorial phenomenon. These results suggest that alisertibmay pro-
vide greater benefit to patients with the VV alleles, which is a biomarker
predictive of poor response to standard-of-care agents. Interestingly, in
both studies, treatment of patients carrying the Aurora A VV SNP at
codon 57 with alisertib was not associated with an increase in response
rate. Additional studies would be useful in order to understand the un-
derlyingmechanism for the effect of alisertib on PFS, but not objective re-
sponse. A preliminary analysis to assess associations between Aurora A
SNP status and safety outcomes found no significant correlation (data
not shown).
It has been reported that Aurora A V57V has higher kinase activity
than Aurora A I57I (Kimura et al., 2005); overexpression and amplifica-
tion of Aurora A are frequently found in solid tumors and are associated
with poor disease outcomes (Chen et al., 2015; Chen et al., 2007;
Ewart-Toland et al., 2005; Hoque et al., 2003; Kimura et al., 2005; Pan
et al., 2012). In multiple preclinical models, Aurora A has been identified
as an oncogene that drives tumor growth and confers chemoresistance
(Sun et al., 2015; Zhang et al., 2014). Consistent with these findings,
the presence of VV alleles at codon 57 (conferring higher kinase activity)
correlated with poor OS in our analysis of TCGA data. Alisertib, as an Au-
rora A protein kinase inhibitor, may deliver greater benefit in patients
with VV alleles and therefore high Aurora A kinase activity. In contrast,
patients with II alleles with a good prognosis may have low Aurora A ki-
nase activity in tumors and for this reason they derive less benefit from
Aurora A inhibition by alisertib. In the NCT01091428 study, II patients
treated with alisertib plus paclitaxel had reduced PFS compared with
paclitaxel treatment alone (9.2 vs. 13.3 months).
This study has a number of limitations. Firstly, these correlative stud-
ies were carried out retrospectively with a limited sample size. The pa-
tient population with blood samples available for genotyping in
NCT01045421 was relatively small (approximately one quarter of the
entire study population). Response measures were not confirmed by in-
dependent review in either study and a limited number of solid tumor
types were assessed. Prospective validation of these observations in an
independent clinical study will be needed to establish the predictive
value of the Aurora A codon 57 SNP. Moreover, the predictive value of
this SNP for alisertib activity may be dependent on additional factors, in-
cluding cancer subtype, whether alisertib is administered as single or
combination therapy, risk stratification, and other predictive biomarkers.
It remains to be seen whether these findings can be applied to other
tumor types including haematological malignancies.
In conclusion, Aurora A SNP genotypewas associatedwith differential
outcomes to alisertib treatment and may have potential as a biomarker
in patients with solid tumors; further investigation is warranted. These
findings may ultimately provide a patient selection strategy for alisertib
treatment.
Fig. 6. PFS in patients receiving alisertib plus paclitaxel vs paclitaxel alone in the NCT01091428 study: A) patients with VV alleles at Aurora A codon 57, and B) overall mITT study
population. CI, confidence interval; HR, hazard ratio; mITT, modified intent-to-treat; PFS, progression-free survival.
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